Treating cancer
A method for treating cancer comprising applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR7, CCR5, CCR6, CCR8, CXCR4, CXCR7, CCR4, CCR9, CCR10, CXCR3 or CXCR5 or to a Treg receptor immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR7, CCR5, CCR6, CCR8, CXCR4, CXCR7, CCR4, CCR9, CCR10, CXCR3 or CXCR5 or Treg receptor expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.
1. A method for treating cancer in a subject in need thereof, which comprises:
applying peripheral blood from the subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to chemokine receptor CCR7 immobilized directly or indirectly on the support, whereby one or more cells expressing chemokine receptor CCR7 are removed from the peripheral blood of the subject; and
returning the applied peripheral blood back to the subject, whereby the cancer is treated, and wherein the cancer is a leukemia.
2. The method of claim 1 , wherein the levels of circulating tumour cells are reduced in the subject.
3. The method of claim 1 , wherein the incidence of tumour metastasis is reduced in the subject.
4. The method of claim 1 , wherein the leukemia is selected from chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and leukemic phase of lymphoma.
5. The method of claim 1 , wherein the binding reagent is an agonist or an antagonist of CCR7.
6. The method of claim 1 , wherein the binding reagent is an antibody or a chemokine.
7. The method of claim 6 , wherein the chemokine is selected from CCL19 and CCL21.
8. The method of claim 7 , wherein the chemokine is CCL19 (MIP-3b) or CCL21 (SLC) and the chemokine receptor is CCR7.
9. The method of claim 1 , wherein the one or more cells are B cells, regulatory T cells, tumour cells, central memory T lymphocytes, or regulatory T lymphocytes.
10. The method of claim 1 , wherein the subject has increased levels of expression of CCR7 as compared to a subject that does not have cancer.
11. The method of claim 1 , wherein 20-90% of the subject's blood is applied to the column in a single treatment.
12. The method of claim 1 , wherein treating cancer comprises:
(a) reducing levels of circulating tumour cells in the subject,
(b) reducing the incidence of tumour metastasis in the subject,
(c) removing regulatory T lymphocytes from the peripheral blood of the subject,
(d) debulking in Acute Myeloid Leukemia (AML), or Acute Lymphoblastic Leukemia (ALL) in the subject before harvest for autologous bone marrow/stem cell transplantation, or
(e) any combination of (a)-(d).